Last reviewed · How we verify
NCT06078839: NMSICRCT
Nafamostat Mesilate in the Treatment of Severe Infection-associated Coagulopathy
Phase 4 trial testing Nafamostat mesilate in Sepsis in 778 participants. Not yet recruiting.
1 October 2026
Quick facts
| Lead sponsor | Xu Li |
|---|---|
| Phase | Phase 4 |
| Status | Not yet recruiting |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | treatment |
| Enrollment | 778 |
| Start date | 1 October 2023 |
| Primary completion | 1 October 2026 |
| Estimated completion | 1 October 2026 |
Drugs / interventions tested
- Nafamostat mesilate — full drug profile →
- 5% glucose
Conditions studied
- Sepsis — all drugs for Sepsis →
- Sepsis-induced Coagulopathy — all drugs for Sepsis-induced Coagulopathy →
- Nafamostat Mesilate — all drugs for Nafamostat Mesilate →
Sponsor
Xu Li — full company profile →
Who can join
Adults 18 to 100, any sex, with Sepsis or Sepsis-induced Coagulopathy. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The objective of this study was to evaluate the therapeutic effect of nafamostat mesilate on patients with severe infection-related coagulation。
Publications & conference data
3 peer-reviewed publications reference this trial (live from Europe PMC):
-
The dysfunction of complement and coagulation in diseases: the implications for the therapeutic interventions.
Jiang H, Guo Y, Wang Q, Wang Y, et al · · 2024 · cited 5× · PMID 39445002 · DOI 10.1002/mco2.785 -
Efficacy and safety of nafamostat mesilate for sepsis (EASNMS): study protocol for a multicenter randomized controlled trial.
Yang H, Feng J, Ma Y, Ma X, et al · · 2025 · PMID 40731293 · DOI 10.1186/s13063-025-08979-4 -
Efficacy and safety of Nafamostat Mesilate for sepsis (EASNMS) : study protocol for a multicenter randomized controlled trial
Yang H, Feng J, Ma Y, Ma X, et al · · 2025 · DOI 10.21203/rs.3.rs-6629099/v1
Verify or expand the search:
- PubMed search for NCT06078839
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Sepsis
Currently open trials in the same condition.
- NCT07507877 — Infraclavicular Axillary Vein Collapsibility Index as a Predictor of Fluid Responsiveness · recruiting
- NCT07154615 — Assessing Immune Dysfunction in Sepsis · recruiting
- NCT07419802 — OxiCLEAR (Oxiris Cytokines and Endotoxin Adsorption Rate) Study · recruiting
- NCT07351344 — African Survey on Sepsis Knowledge (ASK) · recruiting
- NCT07448805 — Accuracy and Safety of the Syai Tag System for Continuous Glucose Monitoring in Intensive Internal Care Unit · NA · recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06078839 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Xu Li
- Last refreshed: 12 October 2023
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06078839.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing